Authors
Latest:
How Cold Chain Logistics Work in Clinical TrialsWithout question, advanced cellular and gene therapies require well-defined cold-chain management solutions that reduce risk and include all elements of packaging, data collection and logistics expertise to ensure high-quality, effective treatments reach the point of care, and ultimately, the patient.
Latest:
Evaluation of Data for Multi-Regional Trials: A Three-Layer ApproachPlanning for ethnic sensitivity from a scientific and regulatory perspective.
Latest:
Safety 360 – A Holistic Approach to PharmacovigilanceThe industry is experiencing a paradigm shift from pharmacovigilance rooted in case processing and compliance reporting to a safety program built around benefit-risk management.
Latest:
Overcoming Early Phase Oncology ChallengesHow to meet the rigorous safety and efficacy demands critical to evaluating newer targeted cancer therapies.
Latest:
Critical Appraisal of Clinical Quality Assurance Based on Benchmarking Results: Past - Present - FutureA follow-up survey on clinical quality assurance (CQA) assesses current industry best practices compared to a decade ago, and provides recommendations on this key component of quality management for the future.
Latest:
Critical Appraisal of Clinical Quality Assurance Based on Benchmarking Results: Past - Present - FutureA follow-up survey on clinical quality assurance (CQA) assesses current industry best practices compared to a decade ago, and provides recommendations on this key component of quality management for the future.
Latest:
Critical Appraisal of Clinical Quality Assurance Based on Benchmarking Results: Past - Present - FutureA follow-up survey on clinical quality assurance (CQA) assesses current industry best practices compared to a decade ago, and provides recommendations on this key component of quality management for the future.
Latest:
An IRB’s Perspective on ePROThe information in this article serves as a good start by providing factors to keep in mind if your organization is considering adopting ePRO. Appropriateness of ePRO often varies by study and is evaluated individually. As the research landscape continues to shift, being prepared will help ensure a successful IRB review of your study and facilitate a smoother research process overall.
Latest:
An IRB’s Perspective on ePROThe information in this article serves as a good start by providing factors to keep in mind if your organization is considering adopting ePRO. Appropriateness of ePRO often varies by study and is evaluated individually. As the research landscape continues to shift, being prepared will help ensure a successful IRB review of your study and facilitate a smoother research process overall.
Latest:
6 Ways to Protect the Blind in Clinical TrialsAn overview of clinical supply blinding methods in the context of the current research environment.
Latest:
6 Ways to Protect the Blind in Clinical TrialsAn overview of clinical supply blinding methods in the context of the current research environment.
Latest:
6 Ways to Protect the Blind in Clinical TrialsAn overview of clinical supply blinding methods in the context of the current research environment.
Latest:
Evaluation of Data for Multi-Regional Trials: A Three-Layer ApproachPlanning for ethnic sensitivity from a scientific and regulatory perspective.
Latest:
Evaluation of Data for Multi-Regional Trials: A Three-Layer ApproachPlanning for ethnic sensitivity from a scientific and regulatory perspective.
Latest:
Evaluation of Data for Multi-Regional Trials: A Three-Layer ApproachPlanning for ethnic sensitivity from a scientific and regulatory perspective.
Latest:
Evaluation of Data for Multi-Regional Trials: A Three-Layer ApproachPlanning for ethnic sensitivity from a scientific and regulatory perspective.
Latest:
Right Time, Right ChannelIndustry news focusing on the people and organizations who work in the clinical trials profession.
Latest:
Streamline and Improve Study Start-UpWork is needed if true efficiencies are to be gained in clinical trial performance.
Latest:
Evaluation of Data for Multi-Regional Trials: A Three-Layer ApproachPlanning for ethnic sensitivity from a scientific and regulatory perspective.
Latest:
Evaluation of Data for Multi-Regional Trials: A Three-Layer ApproachPlanning for ethnic sensitivity from a scientific and regulatory perspective.
Latest:
Evaluation of Data for Multi-Regional Trials: A Three-Layer ApproachPlanning for ethnic sensitivity from a scientific and regulatory perspective.
Latest:
Type 2 Diabetes Community-Based Recruitment StrategiesCommunity-based recruitment engages multiple stakeholders in a collaborative approach.
Latest:
Patient-Reported Outcomes in Analgesia Clinical Trials for Chronic PainPRO measures enrich the evaluation of treatment effectiveness and help sponsors differentiate products.
Latest:
Integrating Patient Retention StrategiesAddressing patient dropout with an arsenal of tools that leverages both technology and communication.
Latest:
Type 2 Diabetes Community-Based Recruitment StrategiesCommunity-based recruitment engages multiple stakeholders in a collaborative approach.
Latest:
Breaking Down Clinical BarriersThe statistics show that fewer and fewer physicians are willing to take part in trials and that around half of those that do so once never do so again.
Latest:
Biomarker-Driven Oncology TrialsAccelerating the discovery and delivery of personalized medicine.
Latest:
Biomarker-Driven Oncology TrialsAccelerating the discovery and delivery of personalized medicine.
Latest:
Investigators’ Experiences in Cooperation with CROs in Clinical Trials in FinlandWhile several studies and surveys have examined the relationship between sponsors and CROs, there has been little analysis of CRO-investigative site relationships. This study uncovers useful learnings on the positive and negative experiences of investigators in their direct dealings with CROs.
